Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating CNS disorders and rare diseases.
Employees: 1-10
Investors 1
| Date | Name | Website |
| - | Centrecour... | centrecour... |
Mentions in press and media 6
| Date | Title | Description |
| 31.03.2026 | Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 | Jupiter Neurosciences (NASDAQ: JUNS) showcases JOTROL™ platform progress and investor growth strategy at Emerging Growth Conference 91. Jupiter highlights dual-path model targeting CNS disorders and longevity markets, positioning JOTROL™ as... |
| 02.03.2026 | Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 | Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia™ At BIO, Jupiter will discuss its FDA-cleared Phase IIa clinical program in Parkinson's disease. Advancing FDA-Cleared Phase IIa Parkinson's Program Targeting ... |
| 25.02.2026 | Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago | Members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida. Ju... |
| 23.02.2026 | Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution | Repayment Commencement Deferred to April 1, 2026 The amendment does not introduce any new pricing provisions, reset features or additional financing commitments. Core Economic Terms of $6.0 Million Financing Remain Unchanged Jupiter Neurosc... |
| 13.02.2026 | Jupiter Neurosciences Selected as B2i Digital Featured Company | Dual-Path Strategy Targets Neuroinflammation While Expanding its consumer product line Alongside its clinical program, Jupiter is expanding a consumer brand powered by its proprietary JOTROL™ enhanced resveratrol formulation. Clinical-Stage... |
| 04.12.2024 | Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering | Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline targeting neuroinflammation with its uni... |